Back to News
Market Impact: 0.15
Oculis To Present Additional Phase 2 ACUITY Biomarker Data For Privosegtor In Optic Neuritis
Source: Nasdaq
Healthcare & Biotech
Oculis Holding AG announced it will present new biomarker analyses from the Phase 2 ACUITY trial of Privosegtor in patients with acute optic neuritis. The presentation is scheduled for the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto on October 21–23, 2026; the article excerpt provides no analysis results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
OCS0.30
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?
- Disc Medicine prices $450 million stock offering at $75/share
- Alpha Teknova stock tumbles on public offering announcement